Navidea Biopharmaceuticals Inc is a biotechnology company specialized in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
| Website: | www.navidea.com |
| Email: | jlatkin@navidea.com |
| Main Phone: | +1 614 793-7500 |
| Address: | 4995 Bradenton Avenue |
| Address 2: | Suite 240 |
| State: | OH |
| City / Town: | Dublin |
| Country: | US |
| Postal Code: | 43017-3552 |
| Exchange: | AMX |
| CEO: | Jed A. Latkin |
| Employees: | 17 |
| NAICS: | In-Vitro Diagnostic Substance Manufacturing(325413) |
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corp.? You get Steve Brozak, who brings his one-of-a kind perspective on the
When Steve Brozak performs diligence on biotech stocks, he's always looking for an angle. Brozak, president and managing director at WBB Securities, wants to see how new technology platforms
Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He
The U.S. healthcare system is untenable, says Steve Brozak, president of WBB Securities. The solution-oriented Brozak is on the hunt for biotech and medical device companies that fit a new
Technology funds have been all the rage of late, with banks tossing money into them with an enthusiasm last seen during the dot-com boom. Many investors are looking to get a piece of the start-up
Navidea Biopharmaceuticals Inc is a biotechnology company specialized in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
| Website: | www.navidea.com |
| Email: | jlatkin@navidea.com |
| Main Phone: | +1 614 793-7500 |
| Address: | 4995 Bradenton Avenue |
| Address 2: | Suite 240 |
| State: | OH |
| City / Town: | Dublin |
| Country: | US |
| Postal Code: | 43017-3552 |
| Exchange: | AMX |
| CEO: | Jed A. Latkin |
| Employees: | 17 |
| NAICS: | In-Vitro Diagnostic Substance Manufacturing(325413) |
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corp.? You get Steve Brozak, who brings his one-of-a kind perspective on the
When Steve Brozak performs diligence on biotech stocks, he's always looking for an angle. Brozak, president and managing director at WBB Securities, wants to see how new technology platforms
Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He
The U.S. healthcare system is untenable, says Steve Brozak, president of WBB Securities. The solution-oriented Brozak is on the hunt for biotech and medical device companies that fit a new
Technology funds have been all the rage of late, with banks tossing money into them with an enthusiasm last seen during the dot-com boom. Many investors are looking to get a piece of the start-up
| Last Price 2.78 | Change $ -0.0201 | Change % -0.72 | Tick N/A |
| Bid 2.77 | Bid Size 600.00 | Ask 2.80 | Ask Size 500.00 |
| Open 2.80 | High 2.90 | Low 2.75 | Prev Close 2.80 |
| Last Trade | Volume 67,544 | 52 Wk Hi 5.36 | 52 Wk Low 0.61 |
| Market Cap 73.2 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 26,317,411.00 | EPS (TTM) -0.55 | PE Ratio N/A | Exchange NYSE American |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 1 | 11 |
| Number of Buys | 1 | 10 |
| Number of Sells | 0 | 1 |
| Net Activity | 50000 | 527694 |
| Last 10 Buys | Shares |
|---|---|
| William J. Regan | 1,000 |
| Jed A. Latkin | 1,000 |
| Jed A. Latkin | 1,000 |
| Jed A. Latkin | 1,000 |
| Gordon A. Troup | 1,000 |
| Brendan A. Ford | 1,000 |
| Michael M. Goldberg | 1,000 |
| Michael M. Goldberg | 1,000 |
| Brendan A. Ford | 1,000 |
| Mark J. Pykett | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Frederick O. Cope | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 2.4 | 2.4 | 2.4 | 2.4 |
| Low Target Price Estimate | 2.4 | 2.4 | 2.4 | 2.4 |
| Mean Target Price Estimate | 2.4 | 2.4 | 2.4 | 2.4 |
| Standard Deviation | 0 | 0 | 0 | 0 |
| Date of Most Recent Estimate | 04/05/16 | 04/05/16 | 04/05/16 | 04/05/16 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| PRE 14A | Preliminary proxy statement providing notification matters to be brought to a vote | 75 | 2018-06-07 |
| SD | Specialized Disclosure Report | 2 | 2018-05-31 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 52 | 2018-05-09 |
| 8-K | Report of unscheduled material events or corporate changes. | 9 | 2018-05-08 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-04-04 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-04-02 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-03-16 |
| 10-K | Annual report with a comprehensive overview of the company | 135 | 2018-03-15 |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-03-14 |
| 8-K | Report of unscheduled material events or corporate changes. | 9 | 2018-03-08 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 0 | 0 | 0 | 1 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait